Fluxion Biosciences, Stanford collaborate on circulating tumor cell analysis

Friday, June 29, 2012 11:45 AM

Fluxion Biosciences, a San Francisco-based provider of cellular analysis tools for use in critical life science, has formed a collaboration with the Stanford University School of Medicine to develop tests to help deliver more effective therapies to cancer patients.

The collaboration will focus on breast and lung cancer pathologies. The research is designed to help subtype different forms of the disease and develop more effective treatments tailored to each patient.

Dr. Stefanie Jeffrey’s laboratory at Stanford will be utilizing Fluxion’s IsoFlux System to isolate, recover and analyze rare circulating cancer cells at the molecular level. The IsoFlux System utilizes a proprietary microfluidic technology to isolate rare cells with high efficiency. Samples coming from the IsoFlux System are immediately ready for downstream analysis. A variety of analytical techniques are available for isolated cell samples such as mutation detection, gene expression, sequencing, and protein analysis.

“We are very excited to be working with Dr. Jeffrey on this project,” said Michael Schwartz, program director at Fluxion. “She is widely respected as a leader in the field of personalized cancer therapies, and is backed by the support of a world-class medical institution at Stanford.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 17

PPD, Medidata join their technologies for risk-based monitoring, adaptive trial design

ERT acquires eClinical Insights in "strategic combination" to gain cloud-based trial software platform, expertise

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs